Neuracle Science Technology
NS200
| Pipeline | NS200 |
|---|---|
| Summary | NS200 is a peptide drug being developed for the treatment of neurogenic bowel dysfunction (NBD) by promoting intestinal peristalsis through selective activation of galanin type 2 receptors. In neuropathic organ dysfunction due to Parkinson's disease and narcotic analgesic-induced organ dysfunction in terminal cancer patients, the secretion of galanin is inhibited and its receptors are not activated. In addition, hyperkalemia is a common occurrence in patients with renal failure, for which the most common side effects of the treatments are constipation and other gastrointestinal symptoms, which reduce the quality of life (QoL) of many patients. Because NS200 acts directly on galanin type 2 receptors, which are highly distributed in intestinal smooth muscle, it restores intestinal function regardless of the neuropathic condition. Therefore, NS200 is expected to be a new treatment for narcotic analgesic-induced constipation, neuropathic constipation in Parkinson's disease, and hyperkalemia in renal failure, for which there are currently no adequate treatments. |
NS200 promotes intestinal peristalsis by directly activating galanin type 2 receptors (GALR2), which are highly distributed in intestinal smooth muscle.
NS200 restores bowel movements in animal models of opioid-induced constipation (OIC) and shows dose-dependent efficacy across multiple routes of administration.
